Talniflumate

TargetMol
Product Code: TAR-T4503
Supplier: TargetMol
CodeSizePrice
TAR-T4503-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-5mg5mg£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-1mL1 mL * 10 mM (in DMSO)£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-10mg10mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-25mg25mg£225.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-50mg50mg£324.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4503-100mg100mg£450.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome.
CAS:
66898-62-2
Formula:
C21H13F3N2O4
Molecular Weight:
414.34
Pathway:
Membrane transporter/Ion channel; Immunology/Inflammation; Neuroscience; Metabolism
Purity:
0.9993
SMILES:
FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1
Target:
Chloride channel; COX; N-Acetylglucosaminyltransferase; Anion Exchanger

References

Walker N M, et al. Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.[J]. Journal of Pharmacology & Experimental Therapeutics, 2006, 317(1):275-83. Knight D. Talniflumate (Genaera)[J]. Current Opinion in Investigational Drugs, 2004, 5(5):557-62.